Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease

Blood

Volumn 124, Issue 19, 2014, Pages 3016-3019

  Emile, Jean François ^a,b   Diamond, Eli L ^c   Hélias Rodzewicz, Zofia ^a,b   Cohen Aubart, Fleur ^d,e   Charlotte, Frédéric ^d,e   Hyman, David M ^c   Kim, Eunhee ^c   Rampal, Raajit ^c   Patel, Minal ^c   Ganzel, Chezi ^f   Aumann, Shlomzion ^c   Faucher, Gladwys ^a,b   Gall, Catherine Le ^a,b   Leroy, Karen ^g,h   Colombat, Magali ⁱ   Kahn, Jean Emmanuel ⁱ   Trad, Salim ^b   Nizard, Philippe ^j   Donadieu, Jean ^a,d   Taly, Valérie ^j   Amoura, Zahir ^d,e   Abdel Wahab, Omar ^c   Haroche, Julien ^d,e   more..

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f SHAARE ZEDEK MEDICAL CENTER   (Israel)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ Foch Hospital   (France)

^j Universites Paris 12 and Paris 6   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; AKT1 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ARTICLE; CD3+ T LYMPHOCYTE; ERDHEIM CHESTER DISEASE; GENE MUTATION; HISTIOCYTE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOID CELL; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ADULT; AGED; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; POINT MUTATION; RECURRENT DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ERDHEIM-CHESTER DISEASE; FEMALE; GTP PHOSPHOHYDROLASES; HISTIOCYTES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; POINT MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECURRENCE;

EID: 84909643356     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-570937     Document Type: Article

References (21)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed., vol. 2. Geneva, Switzerland: WHO Press; 2008.
2. Arnaud L, Hervier B, Néel A, et al. CNS involvement and treatment with interferon-a are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778-2782.
3. Badalian-Very G, Vergilio J-A, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
4. Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669-683.
5. Emile JF, Charlotte F, Amoura Z, Haroche J. BRAF mutations in Erdheim-Chester disease. J Clin Oncol. 2013;31(3):398.
6. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700-2703.
7. Haroche J, Cohen-Aubart F, Emile J-F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495-1500.
8. Cangi MG, Biavasco R, Cavalli G, et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease [published online ahead of print March 26, 2014]. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204924.
9. Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activating A RAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20):3152-3155.
10. Diamond EL, Abdel-Wahab O, Pentsova E, et al. Detection of an NRAS mutation in Erdheim-Chester disease. Blood. 2013;122(6):1089-1091.
11. Colomba E, Hélias-Rodzewicz Z, Von Deimling A, et al. Detection of BRAF p. V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn. 2013;15(1):94-100.
12. Michonneau D, Kaltenbach S, Derrieux C, et al. BRAFV600E Mutation in a Histiocytic Sarcoma Arising From Hairy Cell Leukemia [published online ahead of print February 24, 2014]. J Clin Oncol. doi:10.1200/JCO.2013.49.0078.
13. Arcila M, Lau C, Nafa K, Ladanyi M. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn. 2011;13(1):64-73.
14. Janku F, Lee JJ, Tsimberidou AM, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE. 2011;6(7):e22769.
15. Abdel-Wahab O, Klimek VM, Gaskell AA, et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov. 2014;4(5):538-545.
16. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14(3):249-256.
17. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
18. Ihle NT, Lemos R Jr, Wipf P, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009;69(1):143-150.
19. Janku F, Hong DS, Fu S, et al. Assessing PIK3C and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Reports. 2014;6(2):377-387.
20. Arceci R, Allen CE, Dunkel I, et al. Evaluation of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. [Abstract 802] Blood. 2013;122:2907.
21. Vaglio A, Gianfreda D, Federico A, Galetti M, Nicastro M, Buzio C. Sirolimus plus prednisone for Erdheim-Chester disease: a pilot trial. American College of Rheumatology Annual Meeting. 2013:A789.